Skip to content
Search

Latest Stories

UK extends partnership with FIND to combat antimicrobial resistance

UK extends partnership with FIND to combat antimicrobial resistance

FIND receives new 4-year funding from the UK government to develop innovative and accessible diagnostics 

The UK Department of Health and Social Care (DHSC) has signed a new US$10 million (7.8 million pounds) grant agreement with global non-profit organisation, FIND.


This extends the UK government’s support to FIND through the Global AMR Innovation Fund (GAMRIF) for another four years.

FIND recently announced the GAMRIF funding, which will be used to support its three-pronged strategy to prevent AMR emergence and halt its development.

Dr Cassandra Kelly-Cirino, Vice President, Health Programmes at FIND, said: “Lack of essential diagnostics that can be accessed by people when and where they are needed is jeopardizing global efforts to combat AMR everywhere. We are grateful to GAMRIF for the continued support as we work in partnership on this multi-faceted strategy to save lives.”

Dame Sally Davies, UK Special Envoy on AMR, highlighted that antimicrobial resistance (AMR) is a global threat, leading to 1.25 million deaths across the world each year, with the highest burden in low- and middle-income countries.

Commenting on the renewed FIND–GAMRIF partnership to develop innovative and accessible diagnostics, she said: “These tests and digital tools will aid clinical decision-making, ensuring that patients get the most appropriate treatment when they need it, as well as improving data collection to enhance our understanding of AMR locally and globally.”

By 2050, the number of deaths due to AMR is expected to increase to 10 million deaths per year.

The rise in AMR is projected to result in a 25 per cent increase in healthcare costs in low-income countries by 2050, compared to a six per cent increase in high-income countries.

Through GAMRIF, the UK supports research and development around the world to reduce the threat of antimicrobial resistance in low- and middle-income countries. The new funding will extend its support to FIND for a period of 4 years, from 2023 to 2027.

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less
NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Pharmacy First: Government confirms £215 million boost to realise its full potential

From April 2025, the consultation fee for Pharmacy First Minor Illness and Clinical Pathways will rise from £15 to £17.

‘Pharmacy First hasn't realised its full potential,’ says Stephen Kinnock

Health Minister Stephen Kinnock has acknowledged that Pharmacy First has huge potential, noting that the service “hasn't realised its full potential.”

As part of efforts to enhance the service, Kinnock yesterday (30) announced £215 million in additional funding for Pharmacy First and other Primary Care Access Recovery Plan services.

Keep ReadingShow less
New CPCF funding: “This is the best deal community pharmacy has had in a decade”

This new funding settlement marks a significant step forward in addressing the long term underinvestment in community pharmacy, says RPS England chair Tase Oputu

Pharmacy bodies hail new funding settlement as ‘best deal for community pharmacy in a decade’

Pharmacy bodies have welcomed the new funding settlement for community pharmacies, highlighting its potential to enhance patient access to care and medicines while addressing a decade of underinvestment in the sector.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a record £3.073 billion funding package for 2025/26, along with an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less